|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Once a broad tumor class is established, more specific differentiation markers can be pursued (e.g., lineage-restricted transcription factors for adenocarcinoma; p40 for squamous cell carcinoma; chromogranin A and synaptophysin or INSM1 for neuroendocrine neoplasms).
|
31786484 |
2020 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, high p63 expression revealed a significant correlation with age (p=0.035), tumor type (p=0.004), American Joint Committee on Cancer stage (p=0.046), lymph node metastasis (p=0.006), lymphovascular invasion (p=0.006), distant metastasis (p=0.049), high Ki67 expression (p=0.000) and K-ras expression (p=0.002).
|
31056618 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TP63 is a member of the TP53 gene family, sharing a common gene structure that produces two groups of mRNAs' encoding proteins with different N-terminal regions (ΔN and TA isoforms); both transcripts are also subjected to alternative splicing mechanisms at C-terminus, generating a variety of isoforms. p63 is a master regulator of epidermal development and homoeostasis as well as an important player in tumorigenesis and cancer progression with both oncogenic and tumour suppressive roles.
|
31789342 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor was negative for pituitary markers and weakly positive for p63.
|
31491579 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The selected markers included CK5/6, p40, CK19, BerEP4, p16 and SOX10.All tumors were CK5/6 and p40 positive.
|
31548087 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor protein p63encoded by the gene TP63 acts as a homologue of p53 protein.
|
31493739 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In conclusion, our data provide novel mechanistic insights into the role of TP63 loss in HNSCC initiation and progression, and provide a rationale for the development of new therapeutic approaches specifically targeting TP63-dependent tumor pathways.
|
30910837 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Adamantinoma-like Ewing sarcoma (ALES) is a rare tumor that demonstrates the EWSR1-FLI1 translocation characteristic of Ewing sarcoma despite overt epithelial differentiation including diffuse expression of cytokeratins and p40.
|
30285997 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry analysis of the tumor tissue showed CK5/6 (+), p63 (+), CD56 (+), and Ki-67 (+, approximately 30%), and genetic testing detected no <i>EGFR</i> mutation.
|
31417937 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
TP63 (p63), a member of the tumor suppressor TP53 (p53) gene family, is essential for ectodermal tissue development and suppresses malignant progression of carcinomas.
|
30986748 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The tumor failed to express p63 and cytokeratin 5/6, whereas it was intensively positive for CK7 and E-cadherin.CDX2 expression was weak and focal.
|
29672360 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We further define the interactions of keratinocyte PKK with TP63 and NF-κB signaling, highlighting the importance of this protein as a tumor suppressor in SCC development.
|
29186361 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MED12 is a useful biomarker to diagnose uterine-derived LMS and tumors arising from (LM) with a relatively favorable prognosis.
|
29660202 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Bladder cancer (BC) ranks as the sixth most common cancer in the United States and is the leading cause of death in patients with urinary malignancies. p63 is a member of the p53 family and is believed to function as a tumor suppressor in human BCs.
|
30104251 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor protein 53 (TP53) and its related family of p63 and p73 are tumor suppressor genes that regulate cellular activity to enhance longevity. p53 binds to specific response elements in DNA, modulating the transcription of genes that govern the major defenses against tumor growth.
|
29307398 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These data describe a novel approach for understanding transcriptional activities of TP63 isoforms across a large number of cancer types, potentially enabling identification of patient subsets most likely to benefit from therapies predicated on manipulating specific TP63 isoforms.<b>Significance:</b> Transcriptomic analyses of patient samples and murine knockout models highlight the prognostic role of several critical mechanisms of tumor suppression that are regulated by TP63.<i></i>.
|
29180475 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical staining for cytokeratin cocktail and p63 has been utilized to differentiate between these tumor types.
|
28968268 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
High expression of claudin-7 and low expression of c-kit and protein p63 are associated with higher tumour grade.
|
29475913 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Focal areas of the tumor demonstrated peripheral staining for p63 and CK5/6 suggestive of an in situ component.
|
29028127 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
According to data from molecular cell biology, genetic models and clinic research, we conclude that p63 may act as either an oncogene or a tumor suppressor gene in different scenarios: TA isoforms of p63 gene are generally tumor-suppressive through repressing cell proliferation, survival and metastasis; ΔN isoforms, however, may initiate tumorigenesis via promoting cell proliferation and survival, but inhibit tumor metastasis and progression; effects of p63 on tumor formation and progression depend on the context of the whole p53 family, and either amplification or loss of p63 gene locus can break the balance to cause tumorigenesis.
|
28975366 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemical analysis for expression of cytokeratin (CK) AE1/AE3, CK7, CK5 + 8, CK14, vimentin, p63 and 14-3-3σ highlighted the biphasic nature of the neoplasm.
|
28942309 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As tumor cells showed positive immunostaining for p40 and CK5/6, the immunophenotype of the tumor was consistent with squamous cell carcinoma (SCC).
|
30216599 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Moreover, both NR4A2 and Notch1 suppressed the expression of tumor suppressors p21 and p63.
|
28423575 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In cancer, p63 contribution is isoform-specific, with both oncogenic and tumour suppressive roles attributed, for ΔNp63 and TAp63, respectively.
|
28212728 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The p63 gene is often overexpressed in squamous cell carcinomas; however, how its overexpression contributes to tumor formation and expansion is still incompletely understood.Devos et al. report the development of a versatile mouse model demonstrating that p63 facilitates squamous cell carcinoma formation in skin and providing an excellent tool to dissect the relevance of its downstream signaling pathways in tumorigenesis.
|
28110711 |
2017 |